Covers pharmaceutical grade gelatin properties, Bloom and viscosity ranges, GMP production controls, USP/EP/JP/ChP compliance, BSE/TSE supply requirements, and common capsule, softgel, tablet coating, and binding applications.
Pharmaceutical grade gelatin is a high-purity protein material widely used in capsules, tablets, and other drug delivery systems. Unlike food or industrial gelatin, it must meet strict bioburden, heavy metal, and viscosity requirements to ensure patient safety and manufacturing consistency. This guide covers its core properties, applicable standards, production controls, and common use cases for pharmaceutical manufacturers and formulation teams.
Pharmaceutical grade gelatin is a denatured protein derived from collagen through controlled alkaline, acid, or enzymatic hydrolysis. Raw materials typically include bovine bone, bovine hide, and porcine skin sourced from BSE/TSE-controlled supply chains. The final product forms thermoreversible gels and films, making it suitable for hard capsules, softgels, tablet coatings, and binding applications.
Compared with industrial or food grades, pharmaceutical gelatin is produced under GMP-aligned production controls and tested for critical quality attributes such as gel strength, viscosity, pH, moisture, sulfite content, peroxide value, and microbial limits. These parameters directly influence capsule forming, sealing performance, dissolution behavior, and long-term stability.
For procurement purposes, “pharmaceutical grade” should not be treated as a single universal specification. A batch may be described by gelatin type, raw material source, Bloom strength, viscosity range, particle size, moisture level, and target pharmacopeia. Buyers should confirm the intended dosage form, target market, applicable monograph, and customer-specific acceptance criteria before qualification. The certificate of analysis, BSE/TSE documentation, and agreed specification are normally the key documents used to verify whether a particular lot is suitable for a pharmaceutical application.
The functional performance of pharmaceutical grade gelatin depends on several measurable properties that affect both processing and end-product quality. The values below should be read as typical product or communication ranges rather than universal legal limits. Pharmacopeial requirements, dosage form needs, and customer specifications can differ, so final acceptance criteria should follow the applicable compendium and the batch certificate of analysis.
| Property | Typical Parameter Range | Numerical Attribute / Applicability Note | Relevance to Pharmaceutical Use |
|---|---|---|---|
| Gel strength (Bloom) | 150–280 g | Typical commercial range for capsule and related pharmaceutical grades; exact Bloom grade should be agreed by application and confirmed on COA. | Determines capsule wall firmness, moldability, and mechanical stability |
| Viscosity | 2.5–4.5 mPa·s (6.67%, 60°C) | Typical test-condition range; method, concentration, temperature, and customer limit must be specified. | Affects dipping performance, film thickness, and softgel spread |
| pH | 4.0–6.5 | Typical product range influenced by Type A or Type B processing; not a substitute for monograph or formulation-specific limits. | Influences compatibility with active ingredients and dissolution profile |
| Moisture content | 9.0–13.0% | Typical finished-product control range; acceptable values depend on storage, dosage form, and agreed specification. | Impacts brittleness, flexibility, and microbial stability |
| Heavy metals | ≤20 ppm | General reference level for supplier communication; the applicable elemental impurity or compendial test and limit must follow USP/EP/JP/ChP and customer requirements. | Required for compendial compliance and patient safety |
| Total aerobic count | ≤1000 CFU/g | Typical microbial control target shown as an example; bioburden criteria should be confirmed by dosage form, pharmacopeia, and customer specification. | Controls bioburden for oral dosage form manufacturing |
Type A gelatin, produced by acid processing, usually has a lower pH and higher isoelectric point, while Type B gelatin, produced by alkaline processing, tends to show different viscosity and gelling behavior. Formulators select the appropriate type and Bloom grade based on dosage form requirements, processing equipment, fill characteristics, and compatibility with active ingredients. The distinction matters because two gelatins with the same nominal Bloom can still behave differently if viscosity, moisture, particle size, or raw material source is not controlled.
Bloom strength is most closely linked to gel rigidity and shell mechanics. Higher Bloom grades may support firmer films or stronger capsule walls, but they do not automatically improve every process: a grade that is too firm may require adjustment of dipping, spreading, or drying conditions. Viscosity affects solution handling, film thickness, ribbon formation, and softgel seal behavior. Moisture is linked to brittleness at low levels and tackiness, dimensional change, or microbial risk at high levels. pH and ionic content can affect interactions with active ingredients, plasticizers, colors, and other excipients. For this reason, purchasing decisions should evaluate the combined profile rather than selecting by Bloom alone.
Pharmaceutical grade gelatin may be assessed against major pharmacopeia monographs, including USP, EP, JP, and ChP. These standards address identification, purity, microbial quality, residue levels, and certain functional characteristics, but the exact monograph title, test matrix, acceptance criteria, and applicability can vary by edition and dosage form. Buyers should not assume that a single internal specification automatically satisfies every pharmacopeia; the target market and finished dosage form determine which tests and documentation are required.
| Pharmacopeia / Regulatory Framework | Common Evaluation Dimension | Procurement Interpretation |
|---|---|---|
| USP | Identification, microbial quality, residue on ignition/ash-related controls, heavy metals or elemental impurity considerations, and functional properties where applicable | Confirm the current USP monograph and customer test list; use COA results to verify batch-specific compliance. |
| EP | Identification, purity tests, microbial limits, sulfur dioxide or sulfite-related controls, ash/residue, and animal-origin risk documentation | EU-oriented products often require careful review of BSE/TSE suitability, source traceability, and compendial edition. |
| JP | Identification, purity, microbial attributes, ignition residue or related residue controls, and functional performance | Japanese market submissions should use the applicable JP requirements and customer-approved specification. |
| ChP | Identification, microbial limits, heavy metal or related impurity controls, residue on ignition, and physicochemical properties | Products intended for China should be checked against the current Chinese Pharmacopoeia edition and local registration expectations. |
Manufacturers are also expected to maintain traceability throughout the supply chain, including raw material origin, rendering controls, and purification records. Traceability is particularly important for bovine and porcine materials because regulatory reviewers need to connect source category, collection controls, processing history, and final batch release.
For global markets, additional regulatory expectations may include:
Because gelatin is a material of animal origin, regulatory reviews often focus heavily on source control, transmissible spongiform encephalopathy risk, and viral safety validation. These factors are especially important for products intended for regulated markets such as the EU, the United States, and Japan. A practical qualification file may therefore include the agreed specification, COA, method information, origin/species declaration, BSE/TSE statement, manufacturing process summary, and relevant quality system certificates. The exact document package should be defined during supplier audit or customer review.
The production of pharmaceutical grade gelatin follows a tightly controlled sequence designed to remove impurities while preserving functional gelling properties. Although exact parameters vary by raw material and gelatin type, the core process generally includes the steps below. Each stage affects one or more final quality attributes, so process control is as important as end-product testing.
Approved bovine or porcine raw materials are inspected, cleaned, and size-reduced before processing. Suppliers must provide traceability documentation and health status certification to support pharmaceutical use.
Key control point: species, tissue type, origin, supplier approval, and BSE/TSE status determine regulatory suitability. Incoming inspection, segregation, and cleaning also reduce foreign matter and cross-contamination risk before the material enters chemical conditioning.
Collagen is treated with dilute acid or lime to break non-covalent crosslinks and prepare the material for controlled hydrolysis. This stage strongly influences final gelatin type, Bloom strength, and viscosity.
Key control point: acid treatment normally leads to Type A gelatin, while alkaline treatment is associated with Type B gelatin. Reagent concentration, treatment time, temperature, and washing endpoint affect pH, ionic residue, molecular weight distribution, Bloom, and subsequent extraction behavior.
Gelatin is extracted in successive hot water steps at increasing temperatures. Earlier fractions typically yield higher gel strength, while later fractions may show lower Bloom and higher viscosity.
Key control point: extraction temperature, time, water ratio, and fraction selection influence yield, viscosity, gel strength, color, and molecular degradation. Excessive thermal exposure can reduce gel-forming ability, so temperature profiles are controlled to balance extraction efficiency with functional performance.
Crude gelatin extract undergoes filtration, ion exchange, decolorization, and concentration to reduce salts, color bodies, organic impurities, and microbial load.
Key control point: filtration removes insoluble particles, ion exchange helps control ionic and salt-related impurities, and decolorization supports visual quality. Purification performance should be monitored through conductivity or ash/salt-related indicators, clarity, color, and other agreed tests because residual salts and impurities can affect pH, viscosity stability, and capsule processing.
The purified solution is sterilized by UHT or validated thermal treatment, then gelled, dried, and milled to the required particle size. Finished batches are tested against pharmacopeia and customer specifications before release.
Key control point: validated heat treatment is intended to reduce microbial load while limiting damage to gelling proteins. Drying conditions affect final moisture, brittleness, and storage stability; milling and screening determine particle size, which can influence dissolution, handling, dusting, and mixing. Final release should link process records with Bloom, viscosity, moisture, pH, microbial, and other specification results.
Pharmaceutical grade gelatin is used across multiple dosage forms due to its film-forming ability, gel strength, and established regulatory acceptance. The appropriate grade is not selected by a single parameter; it is matched to the forming process, fill material, moisture sensitivity, dissolution target, and regulatory file. The following table summarizes typical selection considerations without implying a universal formulation rule.
| Dosage Form / Application | Main Gelatin Attributes Reviewed | Typical Processing Concern | Qualification Focus |
|---|---|---|---|
| Two-piece hard capsules | Bloom, viscosity, moisture, film clarity, and setting behavior | Shell brittleness, poor pin formation, dimensional variation, or inconsistent disintegration | Dipping trials, shell mechanics, moisture balance, and batch-to-batch viscosity consistency |
| Softgels | Bloom, viscosity, ribbon strength, plasticizer compatibility, and seal behavior | Ribbon weakness, leakage, seal failure, fill migration, or unsuitable spread during rotary die processing | Ribbon formation, seal integrity, fill compatibility, and thermal processing window |
| Tablet binders and coatings | Viscosity, particle size, solubility, film formation, and pH | Uneven coating, granule over-wetting, dusting, poor adhesion, or changed tablet disintegration | Binder solution behavior, coating uniformity, tablet strength, and dissolution impact |
| Suppositories, lozenges, and specialized matrices | Gel texture, melting or dissolution behavior, purity, and microbial/endotoxin requirements where relevant | Incorrect setting, texture variation, or insufficient purity for the intended use | Application-specific monograph review, pilot trials, and enhanced documentation where required |
Two-piece hard capsules remain one of the largest applications for pharmaceutical grade gelatin. The material provides consistent shell formation, reliable lock closure, and predictable disintegration in the gastrointestinal tract. Hard capsule producers commonly evaluate Bloom and viscosity together because Bloom supports shell firmness, while viscosity affects dipping and film thickness. Moisture control is also central: capsules that are too dry may become brittle, whereas unsuitable moisture levels can contribute to softness or dimensional changes.
For oil-based fills, suspensions, and lipid formulations, gelatin softgels offer accurate dosing, good seal integrity, and improved swallowability. Gelatin viscosity and Bloom strength are critical for ribbon formation and rotary die processing. The gelatin mass must form a flexible ribbon, support the fill without leakage, and maintain a reproducible seal under established processing conditions. Fill compatibility, plasticizer selection, and drying conditions should therefore be assessed during product qualification.
Gelatin can act as a binder in wet granulation or as a component in film coating systems, helping to improve tablet strength, surface finish, and dust control during compression. In binder applications, solution viscosity and particle hydration can influence granule growth and drying. In coating applications, film uniformity and adhesion must be balanced against disintegration and dissolution requirements.
Additional applications include suppository bases, lozenges, hemostatic formulations, plasma expanders, and certain medical device matrices. These uses often require tighter endotoxin, bioburden, or pyrogen controls, and some may require regulatory pathways beyond ordinary oral excipient qualification. Buyers should define the intended use early and confirm whether standard pharmaceutical gelatin documentation is sufficient or whether additional testing and audit information are needed.
When sourcing pharmaceutical grade gelatin, quality teams should evaluate more than certificate-of-analysis values. Consistent batch-to-batch performance depends on raw material control, process validation, and long-term supplier capability. A COA confirms selected test results for a batch, but it does not by itself demonstrate process robustness, change control, traceability, or suitability for the finished dosage form.
Key evaluation points include:
For capsule and softgel manufacturers, even minor viscosity or gel strength variation can lead to shell defects, filling problems, or dissolution failures. That is why pharmaceutical grade gelatin is typically qualified through pilot trials and ongoing supplier monitoring rather than specification review alone. A practical qualification process may include document review, laboratory testing against agreed methods, pilot-scale processing, stability or storage assessment, and periodic review of batch trends.
Frequently asked procurement questions:
What is the difference between Type A and Type B pharmaceutical gelatin? Type A is produced through acid processing and Type B through alkaline processing. They can differ in pH, isoelectric point, viscosity behavior, and interaction with formulation components. Selection should be based on the target dosage form and processing trial rather than type name alone.
How is Bloom strength selected? Bloom is selected according to shell firmness, film formation, equipment conditions, and the required balance between rigidity and flexibility. Hard capsules, softgels, and coating applications do not necessarily use the same Bloom range, so the grade should be matched to the process and confirmed through trials.
Do hard capsules and softgels use the same gelatin? Not necessarily. Hard capsule production emphasizes dipping, setting, shell mechanics, and disintegration. Softgel production additionally requires ribbon formation, plasticizer compatibility, fill compatibility, and rotary die seal performance. Viscosity, Bloom, and moisture windows may therefore differ.
Which documents should be requested? Buyers commonly request the COA, agreed specification, method or test-item summary, species and origin declaration, BSE/TSE statement, and available quality-system certificates. Regulatory submissions or supplier audits may require additional documentation depending on the market and dosage form.
Can Bloom, viscosity, or particle size be discussed for a specific application? These are appropriate specification topics to communicate during sourcing. Suppliers can discuss available grades and existing test items, but final suitability should be established through the buyer’s formulation review, pilot trials, and batch release criteria.
Raw material quality directly impacts production performance and end-product reliability. Beyond Biopharma is a collagen and gelatin manufacturer with ISO 9001 and FDA certification, supplying functional ingredients for food, pharmaceutical, nutraceutical, and related industry applications. The company supports bulk orders and can communicate product specifications according to available grades and documented quality information.
For pharmaceutical grade gelatin projects, specification discussions can cover gelatin type, Bloom strength, viscosity, moisture, particle size, raw material source, target dosage form, and required quality documents. Depending on the grade and existing test program, a technical data sheet may be provided around available identification, physicochemical, microbial, and related inspection items. Buyers should confirm final acceptance criteria against the applicable pharmacopeia, their internal formulation requirements, and the batch COA.
The production team can provide technical consultation on material selection, bulk supply requirements, quality documentation, and processing considerations. For GMP-related expectations, documentation should be reviewed through the customer’s supplier qualification or audit process; available support should be based on confirmed quality-system records rather than assumed certification. Contact us to discuss your application, target specifications, required documentation, and bulk supply needs.
Pharmaceutical grade gelatin is a foundational excipient in oral dosage form manufacturing, combining proven functionality with broad regulatory acceptance. Its performance is determined by a combination of raw material origin, hydrolysis method, purification controls, and final testing against pharmacopeia standards. Parameters such as Bloom, viscosity, pH, moisture, particle size, and microbial quality should be interpreted as part of an agreed specification rather than as isolated numbers. For pharmaceutical manufacturers, selecting a consistent, fully documented gelatin source is essential to maintaining dosage form quality, processing efficiency, and regulatory compliance.
Contact our technical experts for personalized assistance.